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Over the past years, significant efforts have been devoted to explore novel drug
delivery and detection strategies for simultaneous therapy and diagnostics. The
development of biotinylated polyurethane-urea nanoparticles as theranostic 
nanocarriers for targeted drug and plasmid delivery, for fluorescence detection 
of human hepatocellular carcinoma cells, is described herein. These targeted
nanoparticles are specifically designed to incorporate biotin into the polymeric
matrix, since many tumor types overexpress receptors for biotin as a mechanism
to boost uncontrolled cell growth. The obtained nanoparticles were spherical,
exhibited an average diameter ranging 110–145 nm, and showed no cytotoxicity 
in healthy endothelial cells. Biotinylated nanoparticles are selectively incorporated
into the perinuclear and nuclear area of the human hepatocellular carcinoma
cell line, HepG2, in division, but not into growing, healthy, human endothelial
cells. Indeed, the simultaneous incorporation of the anticancer drugs, phenoxodiol
or sunitinib, together with plasmid DNA encoding green fluorescent protein,
into these nanoparticles allows a targeted pharmacological antitumor effect and
furthermore, selective transfection of a reporter gene, to detect these cancer
cells. The combined targeted therapy and detection strategy described here could
be exploited for liver cancer therapy and diagnostics, with a moderate safety
profile, and may also be a potential tool for other types of cancer. 
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1 Introduction 
Cancer therapy and diagnostics are still scientific 
challenges because of the difficulty in achieving a 
targeted drug delivery or an accurate surgical resection 
of the whole tumor tissue [1]. Recent reports point to 
multifunctional nanoparticles as promising tools for 
simultaneous cancer therapy and diagnostics, that is, 
theranostics [2, 3]. Among the numerous developed 
colloidal systems, polymeric matrixes offer new 
possibilities to covalently bind bioactive surface 
molecules in order to target a specific cell type or to 
evade the reticuloendothelial system [4, 5]. In this 
regard, isophorone diisocyanate (IPDI) is a recognized 
monomer that can react with alcohol or amine groups, 
producing polyurethane-urea nanoparticles (PUR NPs) 
[4]. These polymeric NPs are a focus of growing 
interest because of their synthetic versatility, excellent 
mechanical properties, and high biocompatibility [6]. 
To date, many strategies for targeting NPs to cancer 
cells have been tested, including specific antibodies, 
proteins, or peptides [7]. Most of these strategies are 
aimed at binding to a cell surface target that is only 
upregulated in a specific type of cancer. However, 
cancer cells display an array of common traits to 
allow their permanent growth and spreading, such as 
angiogenesis promotion, release of matrix-degrading 
enzymes, and high expression of receptors and 
carriers for nutrients [8]. Namely, biotin receptors have 
been found to be highly active and overexpressed  
in cancer cells [9, 10]. Moreover, emerging evidence 
points to the participation of biotin in cell signaling, 
gene expression, and chromatin structure in cell 
proliferation [11]. Cells accumulate biotin through 
both the sodium-dependent multivitamin transporter 
and monocarboxylate transporter 1. These transporters, 
along with other biotin-binding proteins, drive biotin 
to compartments involved in metabolism, cell growth, 
and division. The activity of certain factors in cell 
signaling pathways, such as biotinyl-AMP, Sp1 and 
Sp3, nuclear factor (NF)-κB, and receptor tyrosine 
kinases is dependent on biotin supply [11]. Therefore, 
surface coating of PUR NPs with biotin, as we show 
in the present study, represents a novel strategy to 
obtain a targeted carrier for different cancer cells and 
can be useful for biomedical diagnostic or therapeutic 
drug delivery to solid tumors. Furthermore, it is well 
known that nanoparticles under 200 nm have the 
additional advantage of accumulating in the tumor 
environment because of the enhanced permeability 
and retention effect (EPR) [12]. The EPR effect des-
cribes the phenomenon of accumulation of molecules 
with a very small size (typically liposomes, NPs, and 
macromolecular drugs) in the tumor microenviron-
ment because of the unique anatomy of tumor vessels. 
Hence, the EPR effect is an additional aid to the 
transport and distribution of the NPs inside tumor 
tissue.  
Hepatocellular carcinoma (HCC) is the third leading 
cause of cancer-related death worldwide and primary 
cause of death in patients with liver cirrhosis [13]. 
Curative therapies can only be offered to roughly 
30% of patients, and these therapies are complicated 
by high recurrence rates and harsh side effects [13]. 
Therefore, new therapeutic strategies are urgently 
needed. An expert panel from the American Associa-
tion for the Study of Liver Diseases has suggested that 
new therapies for HCC should include the combination 
of drugs affecting different signaling pathways or the 
use of multi-target approaches for molecular therapy 
[14]. In this context, tyrosine kinase receptors are high- 
affinity cell surface receptors for many polypeptide 
growth factors, cytokines, and hormones. These 
receptors have a critical role in the development and 
progression of many types of cancer and are being 
used as therapeutic candidates for multi-target drug 
therapy in HCC [15]. Therefore the use of drugs with 
multiple antitumor effects appears to be a promising 
approach for the treatment of HCC.  
Maximal surgical resection of tumors improves 
patient survival [16]. However, success in surgery still 
relies on the surgeon’s ability to delimit the presence 
of residual tumor tissue at the time of surgery. 
Neoplastic tissue limits are virtually indistinguishable 
from normal tissue, pointing to a clear need to improve 
tumor delineation during surgery. In this regard, some 
investigations suggest that DNA/NP hybrids are pro-
mising machinery for gene therapy and diagnostics in 
cancer [17, 18]. These hybrids show clear advantages 
in terms of the use of fluorescein or other imaging 
agents coated to NPs, since it is very difficult to 
implement feasible tumor imaging techniques, which 
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simultaneously offer sufficient specificity and sen-
sitivity. Nanotechnology offers tremendous potential 
for medical diagnostics and novel therapeutic 
modalities. The combination of nanoscale materials 
with multi-target antitumor drugs and a reporter 
gene encoded by plasmid DNA could lead to the 
development of multifunctional medical nanoplatforms 
for simultaneous targeted delivery, fast diagnosis, and 
efficient therapy, resulting in enhanced targeting of 
drugs to diseased cells, as well as better monitoring 
of the therapeutic process. In the present study we 
describe the design and formation of biotinylated PUR 
NPs, for effective targeting of HCC cells in order to 
deliver multi-target drugs, and a reporter gene for 
simultaneous treatment and detection of these cancer 
cells. Current strategies in nanotechnology for linking 
DNA to NPs require positively charged surfaces, 
causing a consequential increase in toxicity to healthy 
cells. In contrast, our methodology does not involve a 
positively charged surface to bind DNA, therefore 
allowing better biosafety for healthy cells. Overall, this 
report could provide new perspectives to overcome the 
current limitations of therapy and diagnostics in HCC, 
by means of state-of-the-art nanostructure tools. 
2 Experimental 
2.1 Materials 
Polyoxyethylene (20) sorbitan monooleate (polysorbate 
80, P80) and saturated medium-chain triglycerides 
(MCT), as nonionic surfactant and oily component, 
respectively, used to prepare oil in water (O/W) nano- 
emulsions were supplied by Fagron (Barcelona, Spain). 
The isophorone diisocyanate (IPDI) monomer and 
the biotin used in the synthesis of PUR NPs, as well 
as the anticancer drugs, phenoxodiol (Phx) and 
sunitinib malate (STB), were purchased from 
Sigma-Aldrich (St. Louis, MO). The N-terminal green 
fluorescence protein (GFP) expression control 
plasmid (pcDNA3.1/NT-GFP) was supplied from Life 
Technologies Ltd. (Paisley, UK). One Shot® Top 10 
Chemically Competent E.coli and Qiagen® Plasmid 
Maxi Kit, used for transformation, amplification, and 
purification of ultrapure, transfection-grade plasmid  
DNA, were purchased from Life Technologies Ltd. 
(Paisley, UK) and Qiagen Inc. (Chatsworth, CA, USA), 
respectively. Super-optimal broth with catabolite 
repression (SOC) medium, Luria broth (LB broth), 
and LB agar ampicillin-100 plates were obtained from 
Sigma-Aldrich (St. Louis, MO). FuGENE® 6 Transfection 
Reagent to determine the transfection efficiency was 
supplied by Roche (Indianapolis, IN, USA).  
Deionized water was obtained from a Milli-Q water 
purification system (Millipore, Molsheim, France).  
Pig and human blood were purchased from AbD 
Serotec (Raleigh, NC, USA). 
Primary human endothelial cells; human umbilical 
vein endothelial cells (HUVECs), and human he-
patocellular carcinoma cells (HepG2) were supplied 
from Life Technologies Ltd. (Paisley, UK) and ATCC 
(Manassas, VA, USA), respectively. Dulbecco’s Modified 
Eagle Medium (DMEM), Ham’s F-12 Nutrient Mix 
(F-12), fetal calf serum (FCS), Dulbecco’s phosphate 
buffered saline (DPBS), endothelial cell growth supple-
ment (ECGS), and penicillin/streptomycin antibiotics 
were purchased from Life Technologies Ltd. (Paisley, 
UK). 
Texas Red-conjugated goat polyclonal anti-biotin 
antibody and Texas Red® dye used in immunocyto-
chemistry studies were obtained from Gene Tex Inc. 
(TX, USA) and Life Technologies Ltd. (Paisley, UK), 
respectively. Atto 565 streptavidin, employed in the 
detection of the biotin coated NPs, was supplied 
from Sigma-Aldrich (St. Louis, MO). Alexa Fluor-488 
wheat germ agglutinin to stain cell membranes was 
purchased from Life Technologies Ltd. (Paisley, UK). 
The mounting medium containing 4′,6-diamidino-2- 
phenylindole (DAPI) was supplied from Vectashield 
(Vector laboratories, Burlingame, CA). 
2.2 Synthesis of biotinylated polyurethane-urea 
nanoparticles 
Biotinylated PUR NPs were obtained by the poly-
addition process from O/W nano-emulsions in the 
water/biotin/P80/MCT/IPDI system. Briefly, 0.01 mmol 
of biotin was solubilized in 1.8 g of water, and then 
incorporated, drop wise, at 25 °C to MCT/P80/IPDI 
mixtures (0.02 g/0.18 g/0.04 mmol, using an oil/ 
surfactant weight ratio of 10/90), under continuous 
mechanical stirring at 2,500 rpm to obtain O/W nano- 
emulsions. Samples were then immediately heated  
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at 70 ± 2 °C in a thermostatic bath for 4 h to achieve 
biotinylated PUR NPs. Afterwards, NPs were freeze- 
dried (Freeze-Dryer Lyoquest, Telstar) and reconstituted 
with 1.8 mL of DPBS just before use for the individual 
studies [19]. 
Phx-loaded and STB-loaded biotinylated PUR NPs 
were prepared by solubilizing 1,000 μg of anticancer 
drug into 0.2 g of MCT/P80/IPDI mixture. Then,  
1.8 g of water solution containing 0.01 mmol of biotin 
was incorporated stepwise to these mixtures, stirring 
continuously until O/W nano-emulsions with a final 
concentration of 90 wt% aqueous component-were 
obtained. Nanoparticles were obtained by heating 
these samples at 70 ± 2 °C. The polyaddition process 
was completed after 4 h, and then samples were 
freeze-dried and reconstituted as described above.  
To obtain biotinylated PUR/pc DNA complex, 
2,000 μg plasmid pcDNA3.1/NT-GFP was previously 
solubilized in 100 μL of water and then incorporated 
into MCT/P80/IPDI or MCT/P80/IPDI/drug mixtures. 
Then, 1.7 g of the aqueous component (biotin/water 
solution at 1/90 weight ratio) was stepwise added  
to form the O/W nano-emulsions. Polyaddition was 
induced by heating samples at 70 ± 2 °C for 4 h, and 
biotinylated PUR/pc DNA complexes were obtained. 
Samples were freeze-dried and reconstituted with 
DPBS, for all studies. Transformation, amplification, 
and purification processes to obtain ultrapure, 
transfection-grade plasmid DNA were carried out 
following the protocols described in the Qiagen® 
Plasmid Maxi Kit. Plasmid concentration was quantified 
at 260 nm by spectrophotometry, using the Take3 
micro-volume plate attached to an Epoch spectro-
photometer (Biotek Instruments, Winooski, VT, USA).  
2.3 Physicochemical characterization of nano-
particles 
Nanoparticle size properties were determined by 
dynamic light scattering (DLS), using a Zetasizer nano 
ZS (Malvern Instruments Ltd., UK). Measurements 
were carried out at 25 °C and at fixed angle of 173°, by 
analyzing the intensity of the scattered light supplied 
by a helium-neon laser (4 mW, λ = 633 nm). The DLS 
data were calculated from the autocorrelation function 
of scattered light by means of two mathematical 
approaches; the cumulants method and the non- 
negatively constrained least squares (NNLS/Contin) 
algorithm, using the Dispersion Technology Software 
nano v. 5.10 (Malvern Instruments Ltd.). Through the 
cumulants analysis, two important parameters are 
obtained; the mean hydrodynamic diameter of the 
NPs (Z-Average) and the width of the particle size 
distribution (Polydispersity index-PDI). To prepare 
samples for the measurements, 20 μL of NP suspension 
was dispersed in 1,480 μL of DPBS, in an ordinary 
cuvette. Reported values of Z-Average and PDI 
corresponded to the average of approximately 40 
measurement runs. 
Stability studies of biotinylated PUR NPs were 
carried out by DLS at 25 °C, measuring the mean 
particle diameter of NP dispersed in culture medium as 
a function of time, for 2 months. Samples were kept at 
4 °C throughout the studied period (62 days) and were 
left to acclimatize at 25 °C before the measurements. 
The size and morphology of different NPs were 
characterised by TEM, using a JEOL JEM 1010 
microscope (JEOL, Akishima, Japan) equipped with 
an AMT XR40 digital imaging camera, at a magni-
fication of 75,000× and a maximum accelerating 
voltage of 100 kV. In prior observation, one droplet of 
NP suspension was placed on a carbon-coated copper 
grid, and negative staining with an aqueous solution 
of uranyl acetate at 1% (w/v) was conducted. Particle 
diameter of approximately 300 randomly selected 
NPs from different TEM images was determined 
using the morphometry software ImageJ v. 1.44 (U.S. 
National Institutes of Health, Bethesda, Maryland, 
USA). 
The incorporation and integrity of biotin in 
biotinylated polyurethane NPs was detected by 
fluorescence, using a fluorescence confocal microscope 
(Leica TCS SP2, Leica Microsystems, Wetzlar, Germany). 
Briefly, non-biotinylated (negative control) and biotiny-
lated PUR NPs were incubated overnight at 4 °C with 
Atto 565 streptavidin complex (1/200). After incubation, 
20 μL of sample was placed on a microscope slide and 
mounted with a coverslip for observation. 
2.4 Cell culture 
HUVECs were cultured in pre-gelatinized plates 
with DMEM/F-12 medium supplemented with 10% 
FCS, 50 U·mL–1 penicillin/streptomycin and 50 μg·mL–1 
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ECGS. Cells were grown at 37 °C and 5% CO2, in    
a water jacketed incubator (Heracell 150i, Thermo 
Scientific, Pittsburgh, USA). HUVECs were passaged 
when they reached 80% confluence and passages 2–5 
were used for all experiments.  
HepG2 cells were cultured with DMEM supple-
mented with 10% FCS and 50 U·mL–1 penicillin/ 
streptomycin. Cells were grown at 37 °C and 5% CO2, 
in a water jacketed incubator (Heracell 150i, Thermo 
Scientific, Pittsburgh, USA).  
2.5 Biological characterisation of nanoparticles 
The hemocompatibility of NPs was evaluated through 
the in vitro red blood cell (RBC) hemolysis test [20]. 
Thereby, an erythrocyte fraction was collected from 
fresh pig and human blood after being centrifuged  
at 5,100 x g, for 10 min, at 4 °C (Heraeus Megafuge 
16R centrifuge, Thermo Scientific, Pittsburgh, USA), 
and then washed three times with DPBS to obtain a 
final stock dispersion of 3 mL of remaining packed 
erythrocytes dispersed into 11 mL of DPBS. Samples 
for analysis were prepared by incorporating 100 μL 
of stock erythrocyte dispersion into 1 mL of the   
NP suspension. Previously, freeze-dried NPs were 
reconstituted in DPBS and then weakly diluted     
in deionized water, to guarantee the isotonicity of  
the NP suspension (osmolality values ranging 280– 
300 mOsm·mL–1). The samples were then incubated 
for 10 min at 37 °C in an Incubator Shaker and after 
that centrifuged for 5 min at 18,000 x g (IEC MicroCL 
21R centrifuge, Thermo Scientific, Pittsburgh, USA). 
The percentage of hemolysis was obtained by com-
paring the absorbance (λ = 540 nm) of the supernatant 
with control samples totally hemolysed with 1 mL of 
deionized water, as previously reported. The blank 
consisted of a blood sample not treated with NPs  
and incubated with 1 mL of DPBS, to obtain only the 
percentage of particle-induced hemolysis. Experiments 
were repeated five times for each sample.  
The cytotoxicity of NPs on cell viability of HUVECs 
and HepG2 was assessed using the CellTiter96 
Aqueous One Solution Cell Proliferation Assay (MTS 
assay, Promega, Madison, WI, USA). Briefly, cells 
were seeded in 96-well plates (pre-gelatinized only 
for HUVECs) at a cell density of 5 × 103 cells per well 
and incubated for 24 h in the corresponding complete  
media, as described above. Then, cells were serum- 
starved for 6 h and afterwards were co-incubated with 
8.5 mg·mL–1 or 1 mg·mL–1 of NPs for 24 h, at 37 °C. 
Just before determination of cell viability, cells were 
washed with DPBS and transferred into starvation 
medium. Cytotoxicity was determined by adding 
20 μL of MTS solution to each well. After 2 h, the 
absorbance was measured at 490 nm using an Epoch 
microplate spectrophotometer (Biotek Instruments, 
Winooski, VT, USA). Cell viability was expressed as 
the absorbance of cells treated with NPs relative to 
cells treated with DPBS (control cells). Each condition 
was performed in sextuplicate and reported as   
mean ± SEM.  
2.6 Immunocytofluorescence studies  
HepG2 and HUVECs were seeded in 2-well Labtek II 
chamber slides (Thermo Scientific, Pittsburgh, USA) 
and grown to 80% confluence. Thereafter, cells were 
incubated with fresh complete medium in the presence 
of 1 mg·mL–1 of biotinylated PUR NPs or non- 
biotinylated PUR with Texas Red dye-incorporated 
NPs for 8 h. After that, cells were washed three times 
with tris-buffered saline (TBS) to keep only endocyted 
NPs, and then cell cultures were fixed with a 1% zinc 
solution for 30 min, at room temperature. Cell slides 
were then incubated with Texas Red-conjugated goat 
polyclonal anti-biotin antibody (1/200) and Alexa 
Fluor-488 wheat germ agglutinin (1/2,500). In addition, 
DAPI mounting medium was used to counterstain 
cell nuclei. Positive signal was detected with a 
fluorescence confocal microscope (Leica TCS SP5, 
Leica Microsystems, Wetzlar, Germany).  
2.7 Transfection studies 
The transfection efficiency of biotinylated PUR/pc 
DNA complexes and the commercial  kit FuGENE 6 
was studied in both HepG2 cells and HUVECs. 
According to the instructions of the FuGENE® 6 kit, 
cells were seeded at a concentration of 5 × 104 cells in 
2-well Labtek II chamber slides and grown with the 
corresponding complete media to 50-80% confluence. 
After that, cells were serum-starved for 6 h and 
co-incubated with 10 μg·mL–1 of plasmid DNA, 1 
mg·mL–1 of biotinylated PUR/pc DNA complex (this 
concentration of NPs correspond to 10 μg·mL–1 of 
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plasmid DNA) or FuGENE® 6 Reagent at a plasmid 
concentration of 10 μg·mL–1 μg/mL and maintaining 
a FuGENE® 6/DNA ratio of 3/1, for 8 more hours. 
Afterwards, cells were washed with DPBS and 
incubated with the corresponding complete medium 
for 48 h to achieve the maximum expression of the 
GFP. Prior to the observation by fluorescence confocal 
microscope, cells were washed with tris-buffered saline 
(TBS), fixed with a 1% zinc solution for 30 min at room 
temperature and placed on a microscope slide and 
mounted with a coverslip using a DAPI mounting 
medium to counterstain cell nuclei.  
2.8 Cell proliferation assays 
The effect of designed NPs on cell proliferation was 
tested in tumor cells (HepG2) as in healthy vascular 
cells (HUVEC).  
Thereby, cells were seeded in 96-well plates 
(previously pre-gelatinized for HUVECs) at a cell 
density of 5 × 103 cells per well and incubated for 24 h 
in the corresponding complete media. After that, cells 
were co-incubated in fresh medium with DPBS, the 
anticancer drugs, or NP formulations at a concentra-
tion of 1 mg·mL–1, for a period of 8 h. The anticancer 
drug concentrations selected for this study were 
20.81 μM for Phx and 9.38 μM for STB, and corres-
ponded to the drug concentrations loaded into 
1 mg·mL–1 of NPs. On the other hand, the dose- 
response profiles of the designed theranostics on 
tumor cell samples at drug concentrations of 41.62 μM, 
10.40 μM, and 5.20 μM for Phx, and 18.77 μM, 4.69 μM, 
and 2.34 μM for STB were also assessed. Afterwards, 
cells were washed three times with DPBS to maintain 
only the particles that had been taken up, and then 
transferreed to serum-free medium for a total period 
of 24 h, to allow the drug to arrest the proliferation. 
Twenty microliters of MTS solution was then incor-
porated into each well for determining the absorbance 
at 490 nm, after 2 h, using an Epoch microplate 
spectrophotometer. Cell viability was calculated as the 
absorbance of nanoparticle-treated cells relative to 
control cells (treated with DPBS). Each condition was 
performed in sextuplicate and reported as mean ± SEM. 
2.9 Statistical analysis 
All data were expressed as mean  standard error 
(SEM). Statistical analysis of the results was per-
formed by one-way analysis of variance (ANOVA) and 
the Newman-Keuls test. Differences were considered 
to be statistically significant at a p-value ≤ 0.05. 
3 Results and Discussion 
3.1 Design and characterization of biotinylated 
polyurethane-urea nanoparticless loaded with a 
reporter gene-containing plasmid and either sunitinib 
or phenoxodiol  
The synthetic procedure to obtain theranostic 
biotinylated polymeric NPs loaded with a reporter 
gene plasmid and one antitumor drug is presented in 
Fig. 1(a). NPs with a biotin-coated surface were achieved 
via a polyaddition process from O/W nano-emulsions 
prepared by the phase inversion composition (PIC) 
emulsification method in the water/biotin/polysorbate 
80/saturated medium chain triglyceride/diisocyanate 
system. The use of biotin to functionalize the polymeric 
matrix is an elegant strategy to achieve a multi-tumor 
nanocarrier, which is able to target cancer cells which 
have a huge requirement for biotin in order to expand 
and invade the environment. Thereby, taking advantage 
of the high binding and uptake of biotin, we designed 
selective nanoplatforms to deliver a reporter gene and 
an antitumor drug to identify and kill cancer cells, 
respectively (Fig. 1(a)). 
Biotin receptors are overexpressed in cancer cells 
and can allow the binding of these biotinylated nano-
particles, facilitating their internalization, thus delivering 
the plasmid for green fluorescent protein (GFP) 
expression, and a multi-target drug (STB or Phx) to 
attack the hepatoma cell, as shown in Fig. 1(b). Both 
STB and Phx have demonstrated to be powerful 
multi-target anticancer drugs, through different 
mechanisms of action, but have also shown harmful 
side effects, in clinical studies [21, 22]. This means 
that they are potential candidates to be employed in 
targeted nanocarriers for the improvement of their 
selectivity, as well as their efficiency, in treating human 
cancers. Moreover, the design of tumor-targeted NPs 
loaded with a reporter gene can provide precise 
identification of the extent of the tumor tissue to be 
surgically excised. 
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Figure 1 Design, uptake, and multi-targeting of biotinylated theranostic nanoplatforms. (a) Design of theranostic nanoparticles with 
anticancer drugs, phenoxodiol or sunitinib malate, and DNA plasmid encoding green fluorescence protein (GFP). (b) Theoretical
mechanism of specific targeting and uptake of theranostic biotinylated polyurethane-urea nanoparticles loading anticancer drugs and 
plasmid DNA, on human hepatoma cells (HepG2). 
  | www.editorialmanager.com/nare/default.asp 
1736 Nano Res. 2015, 8(5): 1729–1745
 
Biotinylated PUR NPs designed in the present study 
were thoroughly characterized. It is well known that 
nanoparticle size plays a key role in cellular uptake, 
interaction with plasma proteins, drug release, toxicity, 
and molecular response [23]. Therefore, size properties 
of biotinylated NPs, such as mean hydrodynamic 
diameter and polydispersity index, were determined 
by DLS at 25 °C (Table 1). Likewise, morphological 
properties of NPs were also evaluated by TEM, as 
shown in Fig. 2.  
As shown in Table 1, NPs exhibited mean hydro-
dynamic diameters ranging between 110–145 nm, 
with narrow particle size distributions (PDI ≤ 0.15). 
Morphological studies by TEM (Fig. 2) evidenced the 
formation of homogeneous populations of isometric, 
spherical shaped NPs with continuous, clearly defined 
limits and estimated particle diameters in the range 
of 76–112 nm. As expected [4], these particle sizes 
were lower than those measured by DLS, since this 
technology actually determines the hydrodynamic 
diameter, whereas data from TEM image analysis 
provide hard-sphere diameters. Tumor targeting 
carriers must be small enough to penetrate through 
transvascular pores and fenestrations in order to reach 
the tumor environment. In this regard, it has been 
reported that the minimum sizes measured for pore 
cutoff, for a limited number of tumor models, are 
around 200–400 nm [24, 25]. Therefore, biotinylated 
nanoparticles with diameters below 150 nm would 
meet the required size properties to be easily 
accumulated in tumor vasculature, taking advantage 
of the enhanced permeability and retention (EPR) effect.  
To evaluate the impact of the culture medium 
components on the size properties, particle diameter 
of biotinylated PUR NPs dispersed in HepG2 culture 
medium was measured by DLS for 62 days (Fig. S1(a)  
Figure 2 Characterization by transmission electron microscopy (TEM) of biotinylated polyurethane-urea (PUR) nanoparticles (NPs).
Micrographs and particle size distribution curves of biotinylated PUR/pc DNA complex (a), phenoxodiol-loaded biotinylated PUR (b), 
phenoxodiol-loaded biotinylated PUR/pcDNA complex (c), sunitinib-loaded biotinylated PUR NPs (d) and sunitinib-loaded biotinylated 
PUR/pcDNA complex (e). 
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Table 1 Size properties (hydrodynamic diameter (Z-Average) 
and polydispersity index (PDI)) of the designed biotinylated 
polyurethane-urea nanoparticles  
Samples(a) Z-Average (nm)(b) PDI
(b)
Biotinylated polyurethane-urea/pc  
DNA complex (Biotin-PUR/pcDNA) 120.2 ± 1.8 0.14
Phenoxodiol-loaded biotinylated  
polyurethane-urea (Phx-Biotin-PUR) 145.1 ± 1.4 0.11
Phenoxodiol-loaded biotinylated  
polyurethane-urea/pcDNA complex  
(Phx-Biotin-PUR/pc DNA) 
142.6 ± 1.5 0.15
Sunitinib -loaded biotinylated  
polyurethane-urea (STB-Biotin PUR) 114.5 ± 1.2 0.11
Sunitinib-loaded biotinylated  
polyurethane-urea/pcDNA complex  
(STB-Biotin-PUR/pcDNA) 
110.9 ± 1.0 0.10
(a) Nanoparticles were synthesized by polyaddition from O/W 
nano-emulsions with 90 wt% and an oil/surfactant weight ratio of 
10/90 in the water/biotin/ polysorbate 80/saturated medium chain 
triglyceride/diisocyanate system; (b)Z-Average and PDI of nano-
particles were determined by dynamic light scattering at 25 °C, 
though the cumulants analysis. 
in the Electronic Supplementary Material (ESM)). 
NPs exhibited moderate kinetic stability during the 
entire study period. Nevertheless, a slight increase of 
the particle diameter, around 15 nm, was produced 
during the first 20 days. This stability profile is in 
accordance with the stability results obtained for 
analogous PUR nanoparticulate systems in aqueous 
dispersion, thus attributing this increase in particle 
size to swelling phenomena during storage at 4 °C 
[19, 26]. Furthermore, the stability of biotinylated PUR 
NPs against aggregation and swelling phenomena 
was considerably improved after the freeze-drying 
process, thus allowing the storage of the samples even 
for a long period (2 years) without any modification 
of size properties (Fig. S1(b) in the ESM). 
The specific uptake of the designed nanovectors by 
cancer cells could be enhanced by conjugating the 
nanocarrier with different ligands, such as peptides, 
proteins, and antibodies. In this context, biotin would 
offer a wide array of possibilities, allowing not only a 
selective targeting to different kinds of cancerous cells 
but also an increase of cellular internalization of NPs 
and a depletion of the reticuloendothelial system 
uptake [27]. The successful incorporation and integrity 
of the biotin in PUR NPs was corroborated by 
fluorescence confocal microscopy after incubating 
NPs with Atto 565 streptavidin complex (Fig. S2 in the 
ESM). A fluorophore conjugated to streptavidin was 
selected because of the high specificity of biotin to 
bind to this protein. Thereby, the detection of positive 
signal (red fluorescence) attributed to the fluorophore 
Atto 565 was indicative of successful incorporation of 
biotin into NPs. Moreover, this revealed that specific 
binding sites of biotin for streptavidin were preserved 
and intact after the polymerization process (Fig. S2(b)). 
In addition, no fluorescence was observed after 
incubating bare PUR NPs (without biotin) with Atto 
565 streptavidin complex (Fig. S2(a)). 
The biosafety of any nanomedicine to come into 
contact with different biological interfaces before 
reaching its therapeutic goal places great importance 
on the designed nanocarriers being safe and innocuous, 
causing no potential damage to these biological 
structures. To study the biocompatibility of NPs, 
hemolysis and cytotoxicity studies were performed 
in erythrocytes of porcine and human origin, and in 
two human cell lines (HUVEC and HepG2) (Fig. S3 
in the ESM). Biotinylated PUR NPs did not show any 
hemolytic effects, either in pig or human erythrocytes, 
demonstrating moderate hemocompatibility. On the 
other hand, NPs also showed a high biocompatibility, 
since no cytotoxicity in HUVECs was observed in the 
MTS assay after being exposed for 24 h at 1 mg·mL–1 
(Fig. S3). Hence, NPs described in the present study 
exhibited a moderate biosafety profile, which makes 
them suitable to be intravenously administered. 
3.2 Specific uptake and perinuclear localization of 
biotinylated PUR NPs in human hepatocellular 
carcinoma cells 
To find out whether functionalization with biotin 
could specifically boost the incorporation of PUR NPs 
in hepatoma cells, we incubated bare NPs loaded with 
Texas Red fluorescent dye and biotinylated NPs with 
the hepatoma cell line HepG2 and the vascular healthy 
endothelial cell line HUVEC (Fig. 3).  
As shown in Figs. 3(a) and 3(c), NPs lacking biotin 
were barely incorporated into tumor and healthy 
vascular cells. In contrast, biotinylated NPs were 
successfully endocyted in HepG2 cells and accumulated 
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close to or within the cell nuclei (Fig. 3(b)). Moreover, 
this uptake and internalization was specific for these 
malignant cells, since extremely low red fluorescent 
signal attributed to the endocytosis of biotinylated PUR 
NPs was observed in HUVECs (Fig. 3(d)). Therefore, 
biotinylation of NPs appears to be a feasible strategy 
that offers an array of possibilities, not only for 
targeting cancer cells in order to deliver drugs, but 
also for gene therapy. Moreover, biotinylated NPs can 
be detected by streptavidin-coated imaging agents, 
specific anti-biotin antibodies, or a combination of 
both systems. This fact potentiates the number of com-
binations in which a drug or a gene of interest can be 
loaded into this type of functionalized NP to achieve 
a targeted therapy and simultaneous diagnosis 
(theranostics). Indeed it is especially important for the 
 
Figure 3 Fluorescent detection of specific uptake and internalization of biotinylated polyurethane-urea (PUR) nanoparticles (NPs) in 
human hepatoma cells (HepG2). Images for (a) and (b) correspond to immunocytofluorescence studies carried out in HepG2 cells, and
(c) and (d) to experiments developed in vascular healthy cells (HUVEC). Cells were treated with bare PUR NPs, encapsulating Texas Red
dye ((a) and (c) images) or with biotinylated PUR NPs ((b) and (d) images), at a concentration of 1 mg·mL–1. Immunofluorescent detection
of NPs is shown in red, cell membranes in green, and cell nuclei in blue. 
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complete resection of the tumor tissue. Current cancer 
therapy usually involves chemotherapy together with 
surgery to remove the tumors, if possible, because 
maximal surgical resection of the tumor may improve 
survival [28]. Nevertheless, success of the surgery 
relies on the surgeon’s ability to visually distinguish the 
presence of residual tumor tissue at the time of surgery 
[29]. Unfortunately, it is very difficult to implement 
feasible tumor imaging techniques that simultaneously 
offer sufficient specificity and sensitivity. For that 
reason the possibility to differentiate between the 
whole tumor mass and the healthy tissue using 
biotinylated NPs, which can be easily coupled to 
imaging agents, can improve the resection process  
by tumor delineation during surgery, with minimal 
or no side-effects. Investigators have proposed the 
use of multiple imaging agents to aid the recognition 
of neoplastic tissue during resection [30, 31]. We have 
shown that imaging agents, coupled to biotinylated 
NPs, can be accumulated in hepatoma cells to help 
identify the tumor tissue. 
3.3 Efficient transfection of plasmid DNA- 
biotinylated NPs and expression of a reporter gene 
in HepG2 cells 
To assess the potential efficacy of gene transfection of 
biotinylated NPs in human hepatocellular carcinoma, 
we incorporated plasmid DNA encoding GFP into 
these NPs, and these were then incubated with HepG2 
cells. In order to establish a range for efficiency, we 
incorporated the same concentration of plasmid 
(10 μg·mL–1) in a commercial kit for transfection 
(FuGENE® 6) and these constructs were incubated 
with HepG2 cells in the same conditions. Results are 
shown in Fig. 4.  
No GFP expression was observed in cancer cells 
incubated with plasmid DNA alone (Control, Fig. 4). 
In contrast, most of the cells expressed GFP after 
incubation with DNA incorporated into the commercial 
transfection reagent (FuGENE® 6, Fig. 4). Surprisingly, 
the incorporation of plasmid DNA into biotinylated 
NPs resulted in a much higher synthesis of GFP in 
HepG2 cells than the commercial kit (biotinylated 
PUR, Fig. 4). This is most likely a consequence of the 
selective accumulation of these NPs into the nucleus 
and its vicinity, hence boosting the rate of transcription 
of messenger RNA producing GFP, and therefore 
exponentially increasing the synthesis of GFP. 
Transfection kits like FuGENE® 6 use liposomes to 
transfer the plasmid DNA, taking advantage of the 
properties of lipid bilayers to fuse with the cell 
membrane to deliver the DNA. However, this strategy 
is not mediated by a targeted and selective delivery 
into the cancer cell, and it is completely dependent 
on a fixed and passive rate of uptake. According to 
our data, the coating of plasmid DNA to biotinylated 
NPs can have great value either for gene therapy in 
HCC or for designing better commercial kits of DNA 
transfection for cancer cells. Moreover, taking advan-
tage of the wide array of ligands, which can be linked 
to these polymeric nanoparticles, different strategies 
could be used to enhance transfection efficiency when 
needed. In this regard, phosphate calcium and virus 
capsid components (adenovirus or retrovirus) have 
demonstrated to be highly effective systems to increase 
gene delivery [32, 33] and could easily be incorporated 
into our formulations, to boost transfection efficiency.  
3.4 The transfection of plasmid DNA-biotinylated 
NPs is not boosted in healthy human endothelial 
cells 
To evaluate whether the uptake of biotinylated NPs 
and therefore, the selective transcription of plasmid 
DNA, was selective in cancer cells, we incubated 
plasmid DNA-biotinylated NPs and DNA-FuGENE® 
6 with vascular healthy cells (isolated HUVECs) 
(Fig. 5). Endothelial cells are the primary cell barrier in 
blood vessels and consequently, are the first biological 
point of contact with an intravenously administered 
formulation. In this regard, it is very important to avoid 
the common undesired effect of peripheral vascular 
toxicity due to the low cell selectivity of traditional drug 
therapies in cancer [34]. 
We did not observe GFP synthesis in HUVECs 
incubated with plasmid DNA alone (Control, Fig. 5). 
On the contrary, roughly 60% of HUVECs expressed 
GFP after incubation with DNA incorporated with 
the transfection kit (FuGENE®6, Fig. 5). On the other 
hand, plasmid DNA-biotinylated NPs showed much 
lower synthesis of GFP in HUVECs than the 
commercial kit (biotinylated PUR, Fig. 5). GFP pre-
sence was detected at very low levels and in less than 
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5% of HUVECs. This means that both the therapeutic 
and diagnostic potential properties of biotinylated 
NPs are selective for human hepatoma cells and are 
not expected to have toxic effects on vasculature, or 
false positives, in the labelling of tumor tissue.  
3.5 Targeted anti-proliferative effects of biotinylated 
PUR NPs loaded with sunitinib or phenoxodiol, in 
human hepatoma cells 
To assess the potential of biotinylated PUR NPs to lead 
a targeted drug delivery effect, aside of gene therapy, 
we incorporated the anticancer drugs: sunitinib and  
phenoxodiol. STB is a multi-target receptor tyrosine 
kinase inhibitor that has been tested as an anti- 
proliferative drug in a wide array of cancers [35–37], 
including hepatocellular carcinoma [21]. 
Similarly, Phx is an anticancer drug that promotes 
cancer cell death through many different mechanisms 
and pathways [38–40]. The multi-target properties of 
anticancer drugs are essential to avoid adaptation of 
cancer cells to the therapy and tumor recurrence. 
Moreover, a major bottleneck in cancer therapy lies in 
achieving specific drug accumulation at tumor tissue, 
because most chemotherapeutic agents are unable to 
 
Figure 4 Transfection efficiency and GFP expression of biotinylated polyurethane-urea (PUR)/plasmid DNA complex and commercial
transfection reagent in human hepatocellular carcinoma cell (HepG2), observed by confocal microscopy. Cells were incubated for 8 h 
with 10 µg·mL–1 of plasmid pcDNA3.1/NT-GFP, with FuGENE® 6 transfection reagent incorporating 10 µg·mL–1 plasmid DNA, or with 
1 mg·mL–1 of biotinylated PUR/pc DNA complex loaded with 10 µg·mL–1 of DNA. Expression of GFP was evaluated after 56 h of 
treatment. Cell nuclei are stained in blue, with DAPI, and the expression of GFP is shown as green fluorescence. 
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differentiate between diseased and healthy cells, 
leading to poor biodistribution and undesired side 
effects. This obstacle could potentially be overcome by 
targeted delivery systems. For this reason, we designed 
different therapeutic strategies, based on biotinylated 
NPs (Biotinylated PUR NPs, Biotinylated PUR/pcDNA 
complex, Phx-loaded biotinylated PUR NPs, Phx- 
loaded biotinylated PUR/pcDNA complex, STB-loaded 
biotinylated PUR NPs and STB-loaded biotinylated 
PUR/pcDNA complex), and tested them in both HepG2 
cells and HUVECs, as shown in Fig. 6.  
According to the results (Fig. 6), both biotinylated 
PUR NPs loaded with Phx and the theranostic coupling 
of Phx + plasmid promoted an approximately 20% 
reduction in HepG2 cell proliferation after 8 h of 
uptake and a total of 24 h of treatment, as compared 
with Phx in suspension (Fig. 6(a)). The exposure time 
is around six times lower than those previously 
reported because we aimed to potentiate the targeted 
effects and to prevent any possible side effects [41]. 
In fact, we also demonstrated that none of the 
formulations incorporating Phx were able to induce 
any toxic effects in cell proliferation of HUVECs after 
8 h of exposure (Fig. 6(b)). Similarly, only biotinylated 
PUR NPs loaded with sunitinib or coupled sunitinib + 
plasmid significantly reduced the proliferation of  
 
Figure 5 Transfection efficiency and GFP expression of biotinylated polyurethane-urea (PUR)/plasmid DNA complex and commercial 
transfection reagent in vascular healthy cells (HUVEC), evaluated by fluorescence confocal microscopy. Cells were treated for 8 h with 
10 µg·mL–1 of plasmid pcDNA3.1/NT-GFP, with FuGENE® 6 transfection reagent containing 10 µg·mL–1 plasmid DNA, or with 
1 mg·mL–1 of biotinylated PUR/pc DNA complex loaded with 10 µg·mL–1 of DNA. Expression of GFP was observed after 56 h of 
treatment. Cell nuclei are stained in blue, with DAPI, and the expression of GFP is shown in green. 
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Figure 6 Evaluation of the specific antiproliferative effects of 
anticancer drug (phenoxodiol or sunitinib malate)-loaded biotinylated 
polyurethane-urea (PUR) nanoparticles (NPs) in human hepatoma 
cells (HepG2) and healthy endothelial cells (HUVEC). Antipro-
liferative effects assessed in (a) HepG2 cells and (b) HUVECs. 
Cell proliferation was determined by the CellTiter96 Aqueous 
One Solution Cell Proliferation Assay (MTS assay) after treating 
cells directly with the antitumor drugs, with 1 mg·mL–1 of drug- 
loaded biotinylated PUR NPs or with 1 mg·mL–1 of theranostic 
NPs (drug-loaded biotinylated PUR/ pcDNA complex). All tested 
formulations were incubated for 8 h, then washed and incubated 
again for 24 h, to evaluate the specific proliferative arrest of only 
internalized NPs. Each column represents the mean ± SEM. # 
p < 0.01, φ p < 0.0001 as compared with control and *p < 0.05, 
**p < 0.01 and ***p < 0.0001 as compared with drug dispersion. 
HepG2 cells (23% and 32% respectively) (Fig. 6(a)) at 
the low exposure time employed, and this inhibitory 
effect resulted in the targeting of these cancer cells, 
since the viability of HUVECs was not affected with 
the same treatment (Fig. 6(b)). Altogether, these results 
indicate that the specific attachment, uptake, and 
effective action of the loaded drug, using both 
functionalized NPs, is restricted to cancer cells, enabling 
the prevention of side effects in healthy vascular cells. 
This is also well illustrated by the result that any 
variation in the concentration employed of the free drug 
alone, for Phx or STB (Figs. 7(a) and 7(c), respectively), 
did not alter the viability of HepG2 cells, at the tested 
concentrations. 
In contrast, biotinylated NPs with Phx did show  
a linear dose-response curve for viability of HepG2 
cells, until a maximum threshold of activity at a 
concentration of 20.81 μM (Fig. 7(b)). Therefore, we 
concluded that 20.81 μM of Phx was the more adequate 
concentration of drug to load in our targeted NPs, in 
order to achieve a good balance between specificity, 
efficacy, and biosafety. On the other hand, biotinylated 
NPs with STB also exhibited a proportional profile of 
cell viability inhibition in HepG2 cells, until the 
maximum effective dose of STB of 18.77 μM (Fig. 7(d)). 
Since increasing the loading of NPs with a dose of 
STB higher than 18.77 μM was technically unviable, 
and the use of higher concentrations than this would 
be closer to other reported studies with free drug [42], 
these data suggest that the best concentration of STB 
for loading to NPs would be between 9.38-18.77 μM. 
The use of biotinylated NPs in this range of STB 
concentration would represent the best choice to 
preserve high activity and selectivity, without causing 
possible toxic effects in healthy vascular endothelial 
cells. Therefore, both treatments with biotinylated 
NPs demonstrated suitability of these nanocarriers to 
successfully target and deliver different multi-target 
anticancer drugs for human hepatocellular carcinoma, 
with an excellent endovascular biosafety profile. On 
the whole, this selective treatment appears to be useful 
to overcome the limitations of current therapy for 
human hepatocellular carcinoma due to harmful side 
effects. Moreover, the simultaneous incorporation of 
drug and plasmid may also help physicians to refine 
surgical procedures, delimitating affected areas of liver 
by means of imaging techniques. Recently, there has 
been a trend towards the improvement of diagnostic 
technologies through the detection of specific 
fluorescent dyes. Our dual carriers can also reach this 
goal, behaving as platforms targeted to cancer, for 
DNA delivery with a powerful inducible mammalian 
expression system to stain cancer cells with GFP. 
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4 Conclusions 
In summary, we have designed biotinylated PUR NPs 
from O/W nano-emulsions in water/biotin/ P80/MCT/ 
IPDI systems, which selectively target human hepa-
toma cells and are able to deliver plasmid DNA and 
drugs for therapy and diagnosis in hepatocellular 
carcinoma. This dual theranostic tool takes advantage 
of the very high requirements of cancer cells for biotin, 
in order to grow exponentially. We have demonstrated, 
through the immunocytofluorescence studies per-
formed here, that these NPs are incorporated and 
accumulated in the perinuclear and nuclear area of 
human hepatoma cells. Accordingly, the use of 
biotinylated NPs/plasmid reporter complexes allowed 
easy fluorescent detection of hepatoma cells, but not 
human vascular endothelial cells. For this reason, the 
privileged subcellular localization of these NPs in 
cancer cells makes these nanocarriers good candidates  
for targeted gene therapy in cancer. Moreover, we 
have demonstrated that the additional combination 
of these biotinylated NPs with multi-target drugs, 
such as phenoxodiol or sunitinib, reduced the cell 
viability of hepatoma cells but not human endothelial 
cells, thereby exhibiting high specificity for tumor 
cells. Altogether our results support the concept that 
these NPs represent a combination of good theranostic 
properties as well as a good biosafety profile. Therefore, 
these nanocarriers will be useful in enhancing the 
efficiency of current therapy of human hepatocellular 
carcinoma and other cancers, minimizing side effects 
and furthermore, allowing simultaneous cancer 
delineation for precise tumor resection.  
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